Pharmacologic interventions for the management of critical bleeding

Pharmacotherapy

Volumn 27, Issue 9 II SUPPL., 2007, Pages

  Voils, Stacy ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Critical bleeding; Hemostatic agents; Pharmacy

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; CHITOSAN; DESMOPRESSIN ACETATE; FIBRIN GLUE; HEMOSTATIC AGENT; OCTREOTIDE; PHYTOMENADIONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SOMATOSTATIN DERIVATIVE; TRANEXAMIC ACID; VASOPRESSIN; ZEOLITE;

BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMOPHILIA A; HOSPITAL PHARMACY; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; META ANALYSIS; PHARMACIST; REVIEW; STROKE; SYSTEMATIC REVIEW; VON WILLEBRAND DISEASE;

EID: 34548316265     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9part2.69s     Document Type: Review

References (57)

1. Shander A, Goodnough LT. Update on transfusion medicine. Pharmacotherapy 2007;27(9 pt 2):S57-68.
2. Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm 2006;63:1244-53.
3. Reger TB, Roditski D. Bloodless medicine and surgery for patients having cardiac surgery. Crit Care Nurse 2001;21:35-44.
4. Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery: erythropoietin and antifibrinolytics. Can J Anaesth 2001;48:S24-31.
5. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage [online exclusive article]. Thromb J 2004;2:9. Available from http://www.thrombosisjournal.com/content/2/1/9.
6. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002;49:S15-20.
7. Segal S, Shemesh IY, Blumenthal R, et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet 2003;268:266-7.
8. McIlroy DR, Silvers AJ. Recombinant factor VIIa for life-threatening bleeding in high-risk cardiac surgery despite full-dose aprotinin. Anesth Analg 2004;99:27-30.
9. Goodnough LT, Shander A. Evolution in alternatives to blood transfusion. Hematol J 2003;4:87-91.
10. Martyn V, Farmer SL, Wren MN, et al. The theory and practice of bloodless surgery. Transfus Apheresis Sci 2002;27:29-43.
11. Shander A. Surgery without blood. Crit Care Med 2003;31:S708-14.
12. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
13. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006;46:327-38.
14. Carless PA, Henry DA, Moxey AJ, et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004;(1):CD001884.
15. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharm Ther 2005;30:644-58.
16. Donahue MA, Price PM. Aprotinin: antifibrinolytic and antiinflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass. Dynamics 2002;13:16-23.
17. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep 2005;4:368-72.
18. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185-94.
19. Erstad BL. Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery. Ann Pharmacother 2001;35:1075-84.
20. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials [online exclusive article]. BMC Cardiovasc Dis 2005;5:19. Available from http://www.biomedcentral.eom/1471-2261/ 5/19
21. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
22. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;(1):CD001886.
23. Laupacis A, Fergusson D, for the International Study of Peri-operative Transfusion (ISPOT) Investigators. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258-67.
24. Porte RJ, Molenaar IQ, Begliomini B, et al, for the EMSALT Study Group. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000;355:1303-9.
25. Marcel RJ, Stegall WC, Suit CT, et al. Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg 1996;82:1122-5.
26. Himmelreich G, Kierzek B, Neuhaus R Slamer KJ, Jochum M, Riess H. Coagulation changes and the influence of the early perfusate in the course of orthotopic liver transplantation (OLT) when aprotinin is used intraoperatively. Blood Coagul Fibrinolysis 1991;2:51-8.
27. Wegner J. Biochemistry of serine protease inhibitors and their mechanisms of action: a review. J Extra Corpor Technol 2003;35:326-38.
28. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003;126:1498-503.
29. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
30. Hiatt WR. Observational studies of drug safety: aprotinin and the absence of transparency. N Engl J Med 2006;355:2171-3.
31. U.S. Food and Drug Administration. FDA public health advisory: aprotinin injection (marketed as Trasylol). Available from http://www.fda.gov/ cder/drug/advisory/aprotinin20060929.htm. Accessed March 21, 2007.
32. U.S. Food and Drug Administration. FDA statement regarding new Trasylol data [press release]. September 29, 2006. Available from http://www.fda.gov/bbs/topics/NEWS/2006/NEW01472.html. Accessed March 21, 2007.
33. Beierlein W, Scheule AM, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005;79:741-8.
34. U.S. Food and Drug Administration. FDA revises labeling for Trasylol (aprotinin injection) to strengthen safety warnings and limit usage of drug to specific situations [press release]. December 15, 2006. Available from http://www.fda.gov/bbs/topics/NEWS/2006/NEW01529.html Accessed March 21, 2007.
35. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother 2001;35:925-34.
36. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
37. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
38. Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. Neurocrit Care 2004;1:47-51.
39. Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med 1976;294:507-11.
40. 2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997;282:597-602.
41. Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood 1998;91:529-37.
42. Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988;85:806-10.
43. Couch P, Stumpf JL. Management of uremic bleeding. Clin Pharm 1990;9:673-81.
44. Canavese C, Salomone M, Pacitti A, Mangiarotti G, Calitri V. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985;1:867-8.
45. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003,1:682-9.
46. Nevens F. Review article: a critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage. Aliment Pharmacol Ther 2004;20(suppl 3):18-22.
47. Dib N, Oberti F, Cales P. Current management of the complications of portal hypertension: variceal bleeding and ascites. Can Med Assoc J 2006;174:1433-43.
48. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006;40:2170-7.
49. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 2003;(1):CD003249.
50. As AK, Hagen P, Webb JB. Tranexamic acid in the management of postpartum haemorrhage. Br J Obstet Gynaecol 1996;103:1250-1.
51. 1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469-73.
52. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S204-33.
53. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006;166:391-7.
54. Novo Nordisk. NovoSeven® Coagulation Factor VIIa (recombinant activated factor VII) package insert. Bagsvaerd, Denmark; 2006.
55. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9(suppl 1):S61-5.
56. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-77.
57. Hu Q, Brady JO. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding [letter]. Mayo Clin Proc 2004;79:827.